Can-Fite BioPharma (CANF) Cash & Current Investments (2013 - 2025)

Can-Fite BioPharma (CANF) has 13 years of Cash & Current Investments data on file, last reported at $11.5 million in Q4 2025.

• Quarterly Cash & Current Investments rose 46.54% year-over-year to $11.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.5 million (up 46.54% YoY) and the FY2025 annual result came in at $11.5 million, up 46.54% from the prior year.
• Cash & Current Investments rose to $11.5 million in Q4 2025, from $6.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $18.9 million in Q4 2021 to a low of $1.3 million in Q1 2023.
• A 5-year average of $6.3 million and a median of $4.5 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments soared 126.56% — and 2022, when it plunged 84.2%.
• Tracing CANF's Cash & Current Investments over 5 years: stood at $18.9 million in 2021, then sank by 84.2% to $3.0 million in 2022, then jumped by 43.9% to $4.3 million in 2023, then soared by 83.43% to $7.9 million in 2024, then surged by 46.54% to $11.5 million in 2025.
• The last three Cash & Current Investments figures came in at $11.5 million (Q4 2025), $6.5 million (Q2 2025), and $7.9 million (Q4 2024), per Business Quant data.